Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications

The development of coagulation factor VIII (FVIII) inhibitory antibodies is a serious complication in hemophilia A (HA) patients after FVIII replacement therapy. Inhibitors render regular prophylaxis ineffective and increase the risk of morbidity and mortality. Immune tolerance induction (ITI) regim...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Liping, Zheng, Qiaoyun, Chen, Zhenyu, Huang, Meijuan, Fu, Lin, Hu, Jianda, Shi, Qizhen, Chen, Yingyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774473/
https://www.ncbi.nlm.nih.gov/pubmed/36569839
http://dx.doi.org/10.3389/fimmu.2022.1019275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774473/
https://www.ncbi.nlm.nih.gov/pubmed/36569839
http://dx.doi.org/10.3389/fimmu.2022.1019275

Ejemplares similares